BNB Plus Corp. BNBX

FY2025 · ended Sep 30, 2025 · Revenue $2.14M, +1.1% YoY · Filed Dec 22, 2025

BNB Plus Corp. (BNBX) files with the SEC under industry code 6199, Finance Services. In fiscal 2025, which ended Sep 30, 2025, it reported revenue of $2.1 million and a net loss of $15.2 million. Free cash flow was -$12.6 million. As of Jun 30, 2026 it held $3.8 million in cash and investments and $193,250 in total debt.

Revenue (TTM)
$2.39M
-1.3% vs year-ago TTM
Net income (TTM)
$-35.22M
-167.1% vs year-ago TTM
Operating cash flow (TTM)
$-11.68M
Free cash flow
$-12.56M
-2.9% vs prior year
EPS (TTM)
$-6.37
+98.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
4.37M
-91.7% vs prior year
Net cash
$3.57M
as of Jun 30, 2026
Operating margin
-1449.2%
FY 2026

Company profile

Industry
Finance Services (SIC 6199)
Listed as
BNBX (OTC)
Fiscal year ends
September 30
Incorporated in
DE
Headquarters
Stony Brook, NY
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
744452
Former names
APPLIED DNA SCIENCES INC (until Nov 10, 2025); PROHEALTH MEDICAL TECHNOLOGIES INC (until Dec 18, 2002); DCC ACQUISITION CORP (until May 4, 2001); DATALINK CAPITAL CORP/TX/ (until Feb 8, 1999)

Other Finance Services companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

Line
FY 2025
Sep 30, 2025
FY 2024
Sep 30, 2024
FY 2023
Sep 30, 2023
FY 2022
Sep 30, 2022
FY 2021
Sep 30, 2021
Revenue
$2.1M
$2.1M
$13.4M
$18.2M
$9.0M
Operating income
-$16.0M
-$13.7M
-$11.0M
-$14.0M
-$13.3M
Net income
-$15.2M
-$7.0M
-$9.9M
-$8.3M
-$14.3M
Diluted EPS
-$134.23
-$1,366.42
-$15.21
-$0.93
-$2.07
Operating cash flow
-$12.2M
—
—
—
—
Free cash flow
-$12.6M
—
—
—
—
Total assets
$4.4M
$12.8M
$13.7M
$22.3M
$14.4M
Total liabilities
$2.5M
$3.8M
$8.8M
$9.4M
$3.3M
Stockholders' equity
$2.3M
$9.1M
$5.0M
$12.9M
$11.1M
Cash and investments
$1.7M
—
$7.2M
$15.2M
$6.6M
Total debt
$193,250
$739,164
$1.2M
—
—

Recent SEC filings

Recent SEC filings
Form Description Filed Period
8-K/A Amended current report
Material agreement
Oct 2, 2026 Sep 28, 2026
8-K Current report
Regulation FD disclosure
Oct 2, 2026 Oct 2, 2026
8-K Current report
Material agreement
Oct 1, 2026 Sep 28, 2026
8-K Current report
Officer or director change
Sep 3, 2026 Sep 2, 2026
10-Q Quarterly report Aug 13, 2026 Jun 30, 2026
8-K Current report
Material agreement, Agreement ended, Unregistered share sale, Officer or director change
Jul 29, 2026 Jul 23, 2026

Source: SEC EDGAR filings. This is company-reported data, not investment advice.